Format

Send to

Choose Destination
Brain Res. 2010 Sep 2;1350:86-94. doi: 10.1016/j.brainres.2010.01.027. Epub 2010 Jan 21.

"Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations.

Author information

1
Amylin Pharmaceuticals, Inc., San Diego, CA 92121, USA. jonathan.roth@amylin.com

Abstract

Active weight loss and the maintenance of a weight-reduced state elicit potent counter-regulatory responses in multiple neurochemical pathways rendering monotherapy-based anti-obesity agents relatively ineffective. Herein, we highlight potential strategies for overcoming counter-regulatory responses to states of negative energy balance using combinatorial approaches. We discuss methodological and practical considerations for preclinical modeling of additive/synergistic weight loss combinations that have emerged in our translational research program aimed at identifying naturally occurring neurohormonal synergies. As an example of synergy, pharmacological and mechanistic findings with the combined administration of the beta-cell hormone amylin and the adipokine leptin are reviewed. Finally, we briefly discuss what the future landscape of neurohormonal anti-obesity combinations may hold.

PMID:
20096672
DOI:
10.1016/j.brainres.2010.01.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center